Trial Profile
Randomized phase IIb study of Cabazitaxel in metastatic Colorectal Cancer resistant to standard treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms COMETA
- 03 Mar 2014 As per the EudraCT record, the status changed from recruiting to discontinued.
- 06 Jul 2012 New trial record